Discussion {#onco13057-sec-0006}
==========

Combinations of Topo I and Topo II inhibitors have been suggested based on the preclinical data that Topo II levels may be upregulated after administration of a Topo I inhibitor. We enrolled women with MBC who were heavily pretreated on this trial evaluating combination of irinotecan and etoposide. Although the regimen was found to have modest clinical activity in terms of response rates and progression‐free survival (PFS), it had significant side effects, with a majority of patients experiencing a grade 3 or 4 treatment‐related adverse event, and the study was terminated early. Based on our experience, the studied combination regimen dose and schedule is not optimal for patients.

Trial Information {#onco13057-sec-0007}
=================

DiseaseBreast cancerStage of Disease/TreatmentMetastatic / AdvancedPrior TherapyMore than 2 prior regimensType of Study -- 1Phase IIType of Study -- 2Single armPrimary EndpointTime to progressionSecondary EndpointOverall response ateSecondary EndpointSafetySecondary EndpointOverall survivalInvestigator\'s AnalysisActive but too toxic as administered in this study

Drug Information {#onco13057-sec-0008}
================

Drug 1  **Generic/Working Name**Irinotecan **Trade Name**Camptosar **Company Name**Pfizer Oncology **Drug Type**Biological **Drug Class**Topoisomerase I **Dose**100 mg/m^2^ **Route**IV **Schedule of Administration**100 mg/m^2^ every 2 weeks in a 28‐day cycleDrug 2  **Generic/Working Name**Etoposide **Trade Name**VePesid **Drug Class**Topoisomerase II **Dose**50 mg per flat dose **Route**p.o. **Schedule of Administration**50 mg per day for 14 days, then off 2 weeks for a 28‐day cycle

Patient Characteristics {#onco13057-sec-0009}
=======================

Number of Patients, Male0Number of Patients, Female31StageMetastatic breast cancer, prior exposure to anthracycline, taxane, and capecitabine therapyAgeMedian (range): 54 (36--84)Number of Prior Systemic TherapiesMedian (range): 5 (3--14)Performance Status: ECOG0 --- 161 --- 142 --- 100Other Tumor Biology (Number)Triple‐negative breast cancer = 5HR+/HER2 neg = 20HER2 pos = 3Unknown = 3Cancer Types or Histologic SubtypesInvasive ductal carcinoma, 24Invasive lobular carcinoma, 3Inflammatory, 2Unknown, 2

Primary Assessment Method {#onco13057-sec-0010}
=========================

TitleTime to progressionNumber of Patients Enrolled31Number of Patients Evaluable for Toxicity31Number of Patients Evaluated for Efficacy24Evaluation MethodRECIST 1.0Response Assessment PR*n* = 4 (17%)Response Assessment SD*n* = 7 (38%)Response Assessment PD*n* = 11 (45%)(Median) Duration Assessments PFS9 weeks(Median) Duration Assessments TTP63 days(Median) Duration Assessments OS29 weeks

Assessment, Analysis, and Discussion {#onco13057-sec-0012}
====================================

CompletionStudy terminated before completionTerminated ReasonToxicityInvestigator\'s AssessmentActive but too toxic as administered in this study

 {#onco13057-sec-2012}

As single agents, both irinotecan and etoposide have documented activity against breast cancer among patients who have received multiple forms of prior chemotherapy \[[1](#onco13057-bib-0001){ref-type="ref"}\], \[[2](#onco13057-bib-0002){ref-type="ref"}\].

Combinations of Topo I and Topo II inhibitors have been suggested based on the observation that Topo II levels may be upregulated after administration of a Topo I inhibitor \[[3](#onco13057-bib-0003){ref-type="ref"}\]. In addition, Topo II may be able to partially compensate for Topo I, as has been seen in *Saccharomyces cerevisiae* \[[5](#onco13057-bib-0005){ref-type="ref"}\], \[[6](#onco13057-bib-0006){ref-type="ref"}\], permitting maintenance of critical transcriptional functions. This concept has been difficult to realize in the clinic when topotecan and etoposide were administered sequentially \[[4](#onco13057-bib-0004){ref-type="ref"}\]. One explanation may be the lapsed time between administration of the Topo I and Topo II inhibitors in the clinical trial, whereas the preclinical data showed maximal synergy when the Topo II inhibitor was administered immediately after the Topo I inhibitor \[[3](#onco13057-bib-0003){ref-type="ref"}\].

In our trial, the majority of patients had refractory disease with an extensive prior treatment history (see Patient Characteristics for demographics). The combination of irinotecan and etoposide was found to have modest clinical activity, with a 55% response rate by RECIST criteria (Fig. [1](#onco13057-fig-0001){ref-type="fig"}) and median PFS of 9 weeks (range, 3--59). However, there were significant side effects, with \>70% of patients experiencing grade 3 or 4 treatment‐related adverse events, primarily neutropenia. See attached table [1](#onco13057-tbl-0001){ref-type="table"} for details on AEs. All patients on study received maximal symptomatic management, transfusions for cytopenias, growth colony‐stimulating factor when indicated, dose reductions, and drug holidays. Growth colony‐stimulating factor support was needed in 85% of patients who had grade 3 or 4 neutropenia requiring dose reduction. Transfusion support for anemia was needed in 13% of patients.

###### Treatment‐related adverse events

![](onco13057-tbl-0001){#nlm-graphic-1}

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.

![Computed tomography chest showing decrease in left pleural nodule after three cycles of therapy.](onco13057-fig-0001){#onco13057-fig-0001}

The study protocol originally planned to accrue a total of 54 patients and specified early stopping if the response rate was 2 or fewer of the first 21 evaluable patients (9.5%) according to Simon\'s optimal design criteria. At the time of interim analysis, despite a promising response rate, the regimen was determined to be too toxic, and the study was terminated early by the data safety monitoring board and study principal investigator.

The current treatment armamentarium for MBC is expanding with newer targeted therapies that improve PFS and quality of life. As the tumor becomes refractory to more treatments, the current treatment landscape includes evaluating for mutations in driver pathways, assessing the microenvironment, and testing novel targeted therapies. As MBC tumor biology and pathways are better understood, allowing for exploitation with novel targeted therapies, the field is moving away from combination chemotherapy regimens. Although combination chemotherapy does have some role in MBC (e.g., in visceral crisis), it is not ideal for long‐term therapy. Based on our experience, we do not expect the combination of irinotecan and etoposide to be used routinely because of an unacceptable toxicity profile.

[ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: [NCT00693719](https://clinicaltrials.gov/ct2/show/NCT00693719)
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[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).
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